A carregar...
2253. Comparison of Outcomes Between Patients with and without Cystic Fibrosis Treated with Ceftolozane–Tazobactam for Pseudomonas aeruginosa Infections
BACKGROUND: Ceftolozane–tazobactam (C/T) was designed to have enhanced activity against P. aeruginosa and has been shown to retain activity against many isolates that are resistant to other antipseudomonal β-lactams. However, there are no data comparing outcomes in patients with and without cystic f...
Na minha lista:
| Publicado no: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6810076/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1931 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|